Chaoliang Ge
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Chaoliang Ge has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Yong Su
The First Affiliated Hospital of Anhui Medical University
2 shared publications Chengfeng Huang
1 shared publicationEn Liu
1 shared publication- Frank J. Gonzalez
Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA
1 shared publication - Guangji Wang
Jiangsu Provincial Key Laboratory of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing 210009, China
1 shared publication Guannan Yang
1 shared publication
Latest Publications
- 8 September 2026
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 18 (37) , 50586-50603
Engineered Mitochondria-Targeted Biomimetic Hybrid Nanovesicles Ameliorate Rheumatoid Arthritis via Regulating Macrophage Autophagy and cGAS-STING Signaling
Despite decades of intensive investigation, rheumatoid arthritis (RA) remains a therapeutic challenge, primarily attributed to its intricate pathological microenvironment and poorly elucidated etiology. However, mitochondrial dysfunction and abnormal activation of the cGAS-STING signaling pathway play a key role in RA. Herein, we report mitochondria targeted biomimetic nanovesicles (SS31-CB@MM-FNVs/CLT) for the targeted therapy of RA. SS31-CB@MM-FNVs/CLT is constructed by macrophage membrane fusion nanovesicles, which are encapsulated with celastrol (CLT) and functionalized with the chitosan-bilirubin (CS-BR) conjugate and SS-31 peptide. SS31-CB@MM-FNVs/CLT bypasses immune surveillance and prolongs circulatory persistence through macrophage membrane fusion, targets macrophage mitochondria by CS and SS-31 peptide decoration, and scavenges reactive oxygen species (ROS), activates autophagy, and repolarizes macrophages from the M1 to M2 subtypes through the synergistic effects of bilirubin, celastrol, and the nanoplatform. In general, SS31-CB@MM-FNVs/CLT exhibits therapeutic efficacy in vitro and in vivo by scavenging ROS, inhibiting the STING pathway, and enhancing autophagy, thereby regulating macrophage polarization. Taken together, this biomimetic nanoplatform provides a promising basis for safer and more potent therapeutic interventions.
- 8 September 2026
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 18 (37) , 50586-50603
Engineered Mitochondria-Targeted Biomimetic Hybrid Nanovesicles Ameliorate Rheumatoid Arthritis via Regulating Macrophage Autophagy and cGAS-STING Signaling
Despite decades of intensive investigation, rheumatoid arthritis (RA) remains a therapeutic challenge, primarily attributed to its intricate pathological microenvironment and poorly elucidated etiology. However, mitochondrial dysfunction and abnormal activation of the cGAS-STING signaling pathway play a key role in RA. Herein, we report mitochondria targeted biomimetic nanovesicles (SS31-CB@MM-FNVs/CLT) for the targeted therapy of RA. SS31-CB@MM-FNVs/CLT is constructed by macrophage membrane fusion nanovesicles, which are encapsulated with celastrol (CLT) and functionalized with the chitosan-bilirubin (CS-BR) conjugate and SS-31 peptide. SS31-CB@MM-FNVs/CLT bypasses immune surveillance and prolongs circulatory persistence through macrophage membrane fusion, targets macrophage mitochondria by CS and SS-31 peptide decoration, and scavenges reactive oxygen species (ROS), activates autophagy, and repolarizes macrophages from the M1 to M2 subtypes through the synergistic effects of bilirubin, celastrol, and the nanoplatform. In general, SS31-CB@MM-FNVs/CLT exhibits therapeutic efficacy in vitro and in vivo by scavenging ROS, inhibiting the STING pathway, and enhancing autophagy, thereby regulating macrophage polarization. Taken together, this biomimetic nanoplatform provides a promising basis for safer and more potent therapeutic interventions.
- Open Access
- 20 October 2025
- Published by Xia & He Publishing in Journal of Clinical and Translational Hepatology
- Vol. 000 (000) , 000
Inflammation and Mitochondrial Dysfunction in Cirrhotic Cardiomyopathy: Therapeutic Implications
Cirrhotic cardiomyopathy (CCM) is a significant complication of cirrhosis, but its progression and underlying mechanisms remain incompletely understood. This study aimed to investigate dynamic changes in cardiac function, pathology, inflammation, and mitochondrial damage in a mouse model of CCM, and to compare echocardiographic characteristics in patients with cirrhosis.
- 20 October 2025
- Published by Xia & He Publishing in Journal of Clinical and Translational Hepatology
- Vol. 000 (000) , 000
Open AccessInflammation and Mitochondrial Dysfunction in Cirrhotic Cardiomyopathy: Therapeutic Implications
Cirrhotic cardiomyopathy (CCM) is a significant complication of cirrhosis, but its progression and underlying mechanisms remain incompletely understood. This study aimed to investigate dynamic changes in cardiac function, pathology, inflammation, and mitochondrial damage in a mouse model of CCM, and to compare echocardiographic characteristics in patients with cirrhosis.
- Open Access
- 13 January 2020
- Published by Springer Nature in Nature Communications
- Vol. 11 (1) , 1-16
SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis
Farnesoid X receptor (FXR) is a promising target for nonalcoholic steatohepatitis (NASH) and fibrosis. Although various FXR agonists have shown anti-fibrotic effects in diverse preclinical animal models, the response rate and efficacies in clinical trials were not optimum. Here we report that prophylactic but not therapeutic administration of obeticholic acid (OCA) prevents hepatic stellate cell (HSC) activation and fibrogenesis. Activated HSCs show limited response to OCA and other FXR agonists due to enhanced FXR SUMOylation. SUMOylation inhibitors rescue FXR signaling and thereby increasing the efficacy of OCA against HSC activation and fibrosis. FXR upregulates Perilipin-1, a direct target gene of FXR, to stabilize lipid droplets and thereby prevent HSC activation. Therapeutic coadministration of OCA and SUMOylation inhibitors drastically impedes liver fibrosis induced by CCl4, bile duct ligation, and more importantly NASH. In conclusion, we propose a promising therapeutic approach by combining SUMOylation inhibitors and FXR agonists for liver fibrosis.
- 13 January 2020
- Published by Springer Nature in Nature Communications
- Vol. 11 (1) , 1-16
Open AccessSUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis
Farnesoid X receptor (FXR) is a promising target for nonalcoholic steatohepatitis (NASH) and fibrosis. Although various FXR agonists have shown anti-fibrotic effects in diverse preclinical animal models, the response rate and efficacies in clinical trials were not optimum. Here we report that prophylactic but not therapeutic administration of obeticholic acid (OCA) prevents hepatic stellate cell (HSC) activation and fibrogenesis. Activated HSCs show limited response to OCA and other FXR agonists due to enhanced FXR SUMOylation. SUMOylation inhibitors rescue FXR signaling and thereby increasing the efficacy of OCA against HSC activation and fibrosis. FXR upregulates Perilipin-1, a direct target gene of FXR, to stabilize lipid droplets and thereby prevent HSC activation. Therapeutic coadministration of OCA and SUMOylation inhibitors drastically impedes liver fibrosis induced by CCl4, bile duct ligation, and more importantly NASH. In conclusion, we propose a promising therapeutic approach by combining SUMOylation inhibitors and FXR agonists for liver fibrosis.